DALLAS, March 24, 2014 /PRNewswire/ -- Securities lawyers at Deans & Lyons announce an investigation of the board of Geron Corporation (NASDAQ: GERN). Concerned GERN investors who purchased between June 16, 2013 and March 11, 2014 are encouraged to contact securities attorney Hamilton Lindley by clicking here.
"After the March 12, 2014 announcement that the FDA put Geron's Investigational New Drug application for imetelstat on full clinical hold, stock plummeted more than 60%," said securities lawyer Hamilton Lindley. "Our potential shareholder lawsuit will seek to ensure that all relevant information is disclosed to Geron Corporation shareholders."
Deans & Lyons has significant experience representing shareholders in securities lawsuits nationwide. GERN stockholders – or anyone with knowledge about this situation – should contact lawyer Hamilton Lindley at email@example.com or 877-819-8033 with questions or concerns.